How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Infusion Pharmacy Management Market
- By Service Type: Compounding Services, Medication Preparation and Dispensing, Patient Education and Counseling, Adherence Monitoring, Clinical Consultation
- By End User: Hospitals, Home Healthcare Agencies, Specialty Clinics, Ambulatory Surgical Centers, Long-term Care Facilities
- By Drug Type: Chemotherapy Drugs, Biologics, Antibiotics, Pain Management Medications, Total Parenteral Nutrition (TPN)
- By Delivery Mode: Intravenous Infusion, Subcutaneous Infusion, Epidural Infusion, Intramuscular Infusion, Intra-arterial Infusion
- By Technology Utilization: Automated Dispensing Systems, Electronic Health Records Integration, Barcoding and RFID Tracking, Telepharmacy Services, Infusion Pump Management
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Compounding Services leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 310 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Infusion Pharmacy Management Market report
A complete, evidence-based study - 12 chapters and 130 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
End User 5
Drug Type 5
Delivery Mode 5
Technology Utilization 5
Companies profiled
Baxter International Inc.
B. Braun Melsungen AG
Fresenius Kabi
Hospira (a Pfizer company)
McKesson Corporation
AmerisourceBergen Corporation
Cardinal Health Inc.
Omnicell Inc.
CareFusion Corporation (now part of BD)
Smiths Medical (part of ICU Medical)
Accredo Health Group
Inc. (a CVS Health company)
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hospira (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →McKesson Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AmerisourceBergen Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cardinal Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Omnicell Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →CareFusion Corporation (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Smiths Medical (part of ICU Medical)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Accredo Health Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Inc. (a CVS Health company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Option Care Health Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →BioScrip Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Avella Specialty Pharmacy
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Diplomat Pharmacy
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,029M by 2033 · 11.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Compounding Services36.6
- Medication Preparation and Dispensing17.0
- Patient Education and Counseling14.0
- Adherence Monitoring17.0
- Clinical Consultation15.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$278.9M → $647.7M · 11.1%
Europe$194.4M → $466.4M · 11.6%
Asia Pacific$177.5M → $465.9M · 12.8%
Latin America$109.9M → $276.3M · 12.2%
Middle East and Africa$84.5M → $195.8M · 11.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.522026
11.532027
11.542028
11.562029
11.562030
11.582031
11.592032
11.602033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.25.9
- B. Braun Melsungen AG21.8
- Fresenius Kabi6.9
- Hospira (a Pfizer company)7.3
- McKesson Corporation5.5
- AmerisourceBergen Corporation4.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type23.4%
End User8.1%
Drug Type25.1%
Delivery Mode22.5%
Technology Utilization21.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe22.7
- Asia Pacific22.7
- Latin America13.5
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 79 | 89 | 94 | 78 | 86 | 92 | 86 |
| B. Braun Melsungen AG | 86 | 75 | 89 | 93 | 90 | 91 | 87 |
| Fresenius Kabi | 64 | 70 | 80 | 80 | 82 | 75 | 75 |
| Hospira (a Pfizer company) | 76 | 75 | 79 | 58 | 62 | 64 | 69 |
| McKesson Corporation | 59 | 76 | 60 | 58 | 63 | 72 | 65 |
| AmerisourceBergen Corporation | 55 | 59 | 47 | 59 | 62 | 46 | 55 |
| Cardinal Health Inc. | 49 | 60 | 49 | 64 | 48 | 51 | 54 |
| Omnicell Inc. | 60 | 37 | 47 | 56 | 44 | 41 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- B. Braun Melsungen AG
- Fresenius Kabi
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| B. Braun Melsungen AG | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Fresenius Kabi | ◐ | − | ✓ | ◐ | ◐ | ◐ |
| Hospira (a Pfizer company) | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| McKesson Corporation | − | ◐ | ◐ | − | ◐ | ◐ |
| AmerisourceBergen Corporation | ◐ | − | − | ◐ | ◐ | − |
| Cardinal Health Inc. | − | ◐ | − | ◐ | ◐ | − |
| Omnicell Inc. | ◐ | ◐ | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1B. Braun Melsungen AG87
2Baxter International Inc.86
3Fresenius Kabi75
4Hospira (a Pfizer company)69
5McKesson Corporation65
6AmerisourceBergen Corporation55
7Cardinal Health Inc.54
8Omnicell Inc.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.B. Braun Melsungen AG
Challenger2
Strong scale, closing on the leaders.
Fresenius KabiHospira (a Pfizer company)
Contender1
Focused players with pockets of strength.
McKesson Corporation
Niche3
Specialists in a single segment or region.
AmerisourceBergen CorporationCardinal Health Inc.Omnicell Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Infusion Pharmacy Management Market — a $207M beachhead inside a $2.93B market.
Beachhead (SOM)$207Mobtainable near-term
Serviceable (SAM)$1.20Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Compounding Services
Best fit — highest urgency & budget in Service Type.
Economic buyer80 fit
Medication Preparation and Dispensing
Strong fit — clear ROI and a fast path to value.
End user69 fit
Patient Education and Counseling
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel30%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Infusion Pharmacy Management Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation13%
Closed-won8%
$13.8KCAC
$65KLTV
4.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Infusion Pharmacy Management Market is a high-growth opportunity — $1.43B by 2033, compounding at 10.6%.
TAM · 2025$641Mtoday
TAM · 2033$1.43Bforecast
CAGR10.6%2027–2033
Cumulative$8.92Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.43BTotal addressable market
SAM$576MServiceable available market
SOM$115MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.6% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.43BLarge & growingTAM by 2033 at 10.6% CAGR
$576MServiceable nowreachable with today’s model
$115MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.12BBear6.9% CAGR
$1.43BBase10.6% CAGR
$1.83BBull13.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Infusion Pharmacy Management Market — a $2.51B market by 2033. Plan: grow share from 9.0% to 18.7%.
Market size · 2033$2.51Btotal addressable
Market CAGR7.2%2027–2033
Target share18.7%from 9.0% today
Revenue ambition$469Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 18.7% | On track |
| Revenue | $213M | $469M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.2% | 38.4% | Behind |
| Customer retention | 88.5% | 92.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $67M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Infusion Pharmacy Management Market conversation — a $2.07B market you can size, segment and defend in minutes.
Market size · 2033$2.07Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,781+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$63K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Baxter International Inc.B. Braun Melsungen AGFresenius KabiHospira (a Pfizer company)McKesson CorporationAmerisourceBergen CorporationCardinal Health Inc.Omnicell Inc.+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Infusion Pharmacy Management Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Infusion Pharmacy Management Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Epithelial Stem Cells (Escs) Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCleanroom Filters Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportOral Antihistamines Market
Market size, share, segmentation and regional forecast.
$495M market · 2025 base year
View reportPatient Room Furniture Market
Market size, share, segmentation and regional forecast.
$816M market · 2025 base year
View reportShort Peripheral Intravenous Catheter Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportUltrasound Scanners Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportRetinyl Acetate Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportDittany Of Crete Market
Market size, share, segmentation and regional forecast.
$714M market · 2025 base year
View report4-Methoxybenzyl Alcohol Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportGanoderma Lucidum Polysaccharides Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportRoot Canal Obturator Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportUrethrotome Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.